Institute of Hematology and Blood Transfusion Prague Czech Republic

Zobrazit více v PubMed

Ogawa S. Genetic basis of myelodysplastic syndromes. Proc Japan Acad Ser B Phys Biol Sci. 2020;96:107–121. PubMed PMC

Nagata Y, Maciejewski JP. The functional mechanisms of mutations in myelodysplastic syndrome. Leukemia. 2019;33:2779–2794. PubMed PMC

Májek P, Reicheltová Z, Suttnar J, Cermák J, Dyr JE. Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. Proteome Sci. 2011;9:64. PubMed PMC

Májek P, Reicheltová Z, Suttnar J, Cermák J, Dyr JE. Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. Proteome Sci. 2012;10:31. PubMed PMC

Majek P, Riedelova-Reicheltova Z, Suttnar J, Pecankova K, Cermak J, Dyr JE. Proteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2. Dis Markers. 2014;2014:178709. PubMed PMC

Májek P, Riedelová-Reicheltová Z, Suttnar J, Pečánková K, Cermák J, Dyr JE. Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome. Proteome Sci. 2013;11:14. PubMed PMC

Majek P, Pecankova K, Cermak J, Gasova Z, Dyr JE. Retinol binding protein 4 plasma level in myelodysplastic syndrome subgroups. Int J Lab Hematol. 2015;37:e127–128. PubMed

Majek P, Pecankova K, Cermak J, Gasova Z, Prochazka B, Dyr JE. Alpha-2-HS-glycoprotein plasma level decrease correlates with age in patients with myelodysplastic syndromes. Cancer Biomark. 2017;20:637–639. PubMed